Abstract 2620
Background
Absenteeism and presenteeism (A/P) are scales related to health problems and professional activity in patients and in healthy individuals. For cancer patients in the age of maximum labor productivity (18 to 65 years old), A/P are possibly affected by quality of care, type of cancer, and selection of treatments. The objectives of this study were to clarify via questionnaire the association between quality-of-life (QOL) and A/P, as well as the changes of A/P during clinical course in cancer patients.
Methods
A/P were measured using the validated Japanese version of the World Health Organization Health and Work Performance Questionnaire (WHO-HPQ). QOL was measured using the 5-level EQ-5D version via a portable device with the Apple ResearchKit app.
Results
We received 3983 survey results (healthy individuals, 297; cancer patients, 3686). Presenteeism was clearly different between cancer patients and healthy individuals (absolute/relative presenteeism: 59.3/0.93 and 65.8/1.01, respectively). Examination of the relationship between QOL and A/P using Spearman’s rank correlation coefficient analysis indicated that QOL is significantly correlated with relative presenteeism (r = 0.40, P < 0.001). The labor performance of pancreatic carcinoma patients was low (absolute/relative absenteeism: 68.7/0.29, absolute/relative presenteeism: 43.8/0.68). The A/P in patients with receiving chemotherapy were not maintained compared to in patients receiving surgical treatment (absolute/relative absenteeism: 39/8/0.16 vs. 17.8/0.02, p = 0.04, absolute/relative presenteeism: 55.5/0.83 vs. 62.8/0.95, p < 0.001, respectively).
Conclusions
WHO-HPQ can be used to measure the labor performance in cancer patients. Moreover, A/P was strongly affected by type of cancers and selection of treatments.
Clinical trial identification
Editorial acknowledgement
The research was supported by Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Legal entity responsible for the study
Shunsuke Kondo.
Funding
Project Mirai Cancer Research Grants and Health Labour Sciences Research Grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3264 - A novel preclinical model of RAF-independent MEK1 mutant tumors and its treatment with novel ATP competitive MEK inhibitor
Presenter: Luca Hegedus
Session: Poster Display session 3
Resources:
Abstract
4918 - HER2 inhibition in Aggressive Squamous Cell Carcinomas driven by a common MET Sema Domain Polymorphism
Presenter: Nur Afiqah Mohamed Salleh
Session: Poster Display session 3
Resources:
Abstract
2426 - ADAM9 as a target for lung cancer treatment
Presenter: Yuh-pyng Sher
Session: Poster Display session 3
Resources:
Abstract
5537 - Novel polyurea/polyurethane nanocapsules loaded with a tambjamine analog to improve cancer chemotherapy delivery and safety in lung cancer
Presenter: Marta Perez Hernandez
Session: Poster Display session 3
Resources:
Abstract
1597 - Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer
Presenter: Hsing-pang Hsieh
Session: Poster Display session 3
Resources:
Abstract
3543 - Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status – putative targets
Presenter: Vilde Haakensen
Session: Poster Display session 3
Resources:
Abstract
4111 - Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
Presenter: Asuka Kawachi
Session: Poster Display session 3
Resources:
Abstract
4559 - Treatment with BLU-667, a potent and selective RET inhibitor, provides rapid clearance of ctDNA in Patients with RET-altered Non-Small Cell Lung Cancer (NSCLC) and Thyroid Cancer
Presenter: Giuseppe Curigliano
Session: Poster Display session 3
Resources:
Abstract
2501 - Triple MET/SRC/PIM inhibition in MET addicted tumors
Presenter: Ilaria Attili
Session: Poster Display session 3
Resources:
Abstract
5655 - Bioactivation of napabucasin triggers reactive oxygen species–mediated cancer cell death
Presenter: Fieke Froeling
Session: Poster Display session 3
Resources:
Abstract